Dexketoprofen
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dexketoprofen: From Acute Musculoskeletal Pain to Tendinitis
One-Sentence Summary
Dexketoprofen is a COX-inhibiting NSAID analgesic used internationally for acute pain and musculoskeletal conditions, though it carries no current Saudi Arabia regulatory approval. The TxGNN model predicts it may be effective for Tendinitis, with 0 clinical trials and 1 publication directly supporting this specific direction. The mechanistic rationale is sound, but indication-specific clinical evidence remains insufficient at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No Saudi Arabia authorization; used internationally as an NSAID analgesic for acute pain |
| Predicted New Indication | Tendinitis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 (mechanism-level; no indication-specific RCT) |
| Saudi Arabia Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold (Research Question — indication-specific evidence required) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in the dataset. Based on known pharmacological information, dexketoprofen belongs to the NSAID (non-steroidal anti-inflammatory drug) class and acts as a cyclooxygenase (COX) inhibitor. By blocking COX enzymes, it suppresses prostaglandin synthesis, thereby reducing both inflammation and pain — a well-established class effect across musculoskeletal conditions.
Tendinitis is driven by localized prostaglandin-mediated inflammation within the tendon sheath. This is precisely the pathway targeted by COX inhibition, making the TxGNN prediction mechanistically coherent. NSAIDs as a class are widely used as first-line symptomatic treatment for tendinitis in clinical practice, and dexketoprofen's notable bioavailability and rapid onset of action offer a pharmacokinetic advantage within the class.
That said, no dexketoprofen-specific randomized controlled trial has been registered or published for tendinitis as a primary endpoint. The sole supporting publication addresses broad non-traumatic musculoskeletal pain in the emergency department — a category that includes tendinitis but does not study it as an isolated indication. This limits the evidence level to L4, and a "Hold" decision is appropriate until indication-specific data is generated.
Clinical Trial Evidence
Currently no related clinical trials registered for dexketoprofen in tendinitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30744914 | 2019 | RCT | The American Journal of Emergency Medicine | IV dexketoprofen vs. IV paracetamol for non-traumatic musculoskeletal pain in the ED (causes ranged from tendinitis to muscle spasm and joint injuries); compared analgesic effectiveness between NSAID and paracetamol in an acute setting |
Saudi Arabia Market Information
Dexketoprofen has no registered authorizations in Saudi Arabia. No product listings, dosage forms, or approved indications are available in the SFDA database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between dexketoprofen's COX-inhibitory action and tendinitis is plausible, but the single supporting publication covers a broad musculoskeletal pain category without tendinitis-specific outcomes — insufficient to meet the L3 threshold needed to advance to a "Proceed" recommendation.
To proceed, the following is needed:
- At least one Phase 2 RCT specifically enrolling tendinitis patients, comparing dexketoprofen against placebo or an active NSAID comparator
- MOA data retrieval from DrugBank (DB09214) to complete mechanistic analysis and document COX-1/COX-2 selectivity profile
- Safety data from the package insert (warnings, contraindications) — currently a blocking data gap
- SFDA registration strategy assessment if Saudi Arabia market entry is planned
- Note: Migraine disorder (TxGNN rank #6) and headache disorder (rank #7) carry substantially stronger evidence for dexketoprofen (8 and 12 completed clinical trials respectively, plus meta-analyses) and may represent higher-priority repurposing targets for near-term development decisions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.